Entrada Therapeutics TRDA
NASDAQ TRDA
$5.44 +0.19 (+3.62%)
At close: Nov 11, 2026 · 4:00 PM EST

Entrada Therapeutics (TRDA) Other Non-Current Liabilities (2021)

Updated

Entrada Therapeutics (TRDA) posted Other Non-Current Liabilities of $396,000 for Q4 2021, up 16.8% from the prior quarter.

Analysis

Entrada Therapeutics (TRDA) Other Non-Current Liabilities (2021) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Entrada Therapeutics 205.54 Mn -172.82 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 396,000.00
Sep 30, 2021 339,000.00
API Access

Entrada Therapeutics Other Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-non-current-liabilities&ticker=TRDA&period=max&api_key=YOUR_API_KEY